

09-28-01

PATENT APPLICATION

GAU 1647  
#17/52  
10-3-01IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle, et al.

Serial No.: 09/613,591

Filed: July 10, 2000

For: COMBINATION THERAPY FOR CONDITIONS  
LEADING TO BONE LOSS

Docket No.: A-378CIP5



Group Art Unit No.: 1647

Examiner: E. Kemmerer

TECH CENTER 1600/2900

OCT 01 2001

RECEIVED

INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 form for consideration by the Examiner.

Applicant, by the undersigned attorney, certifies that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Timothy J. Gaul  
Attorney for Applicants  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date:

Please send all future correspondence to:

U.S. Patent Operations/ TJG  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EL360690102US

Date of Deposit: September 26, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum  
Printed Name

Signature